GlassScriptPhysician profile
Debbie Benoit-Harris
NPI 1780688127
$809.99
in general payments reported to CMS, 2019-2025
21 companies · $147 in 2025
The $147 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $151 · 2021: $54.56 · 2022: $47.68 · 2023: $154 · 2024: $109 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $142.28 | 2023-2025 | Azstarys |
| Pfizer INC. | $98.22 | 2019-2023 | |
| Kaleo, INC. | $81.35 | 2019-2022 | |
| Sanofi Pasteur INC. | $68.74 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $59.06 | 2021-2025 | Qelbree, Qelbree |
| Adlon Therapeutics L.P. | $37.23 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $31.66 | 2022-2023 | Vaqta, Gardasil 9, M-M-R II |
| Tris Pharma INC | $27.94 | 2019-2021 | |
| Sobi, INC | $27.22 | 2023 | |
| Neos Therapeutics, LP | $26.07 | 2019-2020 | |
| Glaxosmithkline, LLC. | $24.97 | 2020-2023 | Bexsero, Pediarix |
| Seqirus USA INC | $23.48 | 2025 | Flucelvax |
| Ironshore Pharmaceuticals INC. | $21.49 | 2024 | |
| Novo Nordisk INC | $18.61 | 2023 | Wegovy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $18.23 | 2024 | |
| Shire North American Group INC | $15.91 | 2019 | |
| Genentech USA, INC. | $15.27 | 2020 | |
| Cranial Technologies, INC | $15.09 | 2020 | |
| Biogen, INC. | $13.96 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $8.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Benoit-Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.